EA029703B9 - Новый аллерген из пыльцы амброзии и его применение - Google Patents

Новый аллерген из пыльцы амброзии и его применение

Info

Publication number
EA029703B9
EA029703B9 EA201590303A EA201590303A EA029703B9 EA 029703 B9 EA029703 B9 EA 029703B9 EA 201590303 A EA201590303 A EA 201590303A EA 201590303 A EA201590303 A EA 201590303A EA 029703 B9 EA029703 B9 EA 029703B9
Authority
EA
Eurasian Patent Office
Prior art keywords
polypeptides
ragweed pollen
novel allergen
concerns
novel
Prior art date
Application number
EA201590303A
Other languages
English (en)
Other versions
EA029703B1 (ru
EA201590303A1 (ru
Inventor
Вероник Борда
Летисия Буссьер
Эмманюэль Нони
Тьерри Батар
Анри Шабр
Филипп Муаньон
Жюльен Буле
Максим Леминьон
Original Assignee
Сталлержен
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сталлержен filed Critical Сталлержен
Publication of EA201590303A1 publication Critical patent/EA201590303A1/ru
Publication of EA029703B1 publication Critical patent/EA029703B1/ru
Publication of EA029703B9 publication Critical patent/EA029703B9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)

Abstract

Изобретение, в частности, касается нового основного аллергена из пыльцы амброзии, названного Amb a X, а также его изоаллергенов и изоформ. Фрагменты вышеупомянутых полипептидов и гомологичные полипептиды, в частности гомологичные полипептиды у родственных видов растений, также являются частью изобретения. Изобретение также касается применения данных полипептидов, в частности, для диагностики и профилактики или лечения аллергии.
EA201590303A 2012-08-03 2013-08-05 Новый аллерген из пыльцы амброзии и его применение EA029703B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305972.7A EP2692732A1 (en) 2012-08-03 2012-08-03 Novel allergen from ragweed pollen and uses thereof
PCT/EP2013/066358 WO2014020179A1 (en) 2012-08-03 2013-08-05 Novel allergen from ragweed pollen and uses thereof

Publications (3)

Publication Number Publication Date
EA201590303A1 EA201590303A1 (ru) 2015-07-30
EA029703B1 EA029703B1 (ru) 2018-05-31
EA029703B9 true EA029703B9 (ru) 2018-09-28

Family

ID=48949134

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590303A EA029703B9 (ru) 2012-08-03 2013-08-05 Новый аллерген из пыльцы амброзии и его применение

Country Status (6)

Country Link
US (1) US20150210742A1 (ru)
EP (2) EP2692732A1 (ru)
CN (1) CN104981480A (ru)
CA (1) CA2881039A1 (ru)
EA (1) EA029703B9 (ru)
WO (1) WO2014020179A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3021328B1 (fr) * 2014-05-23 2018-01-05 Angany Inc. Production commerciale de l'allergene amb a1 par expression transitoire chez les plantes
EP2974741A1 (en) 2014-07-16 2016-01-20 Stallergenes Composition of allergen extracts having reduced toxicity and method of production thereof
CN106995491B (zh) * 2016-01-25 2021-12-07 欧蒙医学实验诊断股份公司 澳洲坚果过敏原
CN109939227B (zh) * 2018-03-23 2023-04-28 中国医学科学院北京协和医院 一种豚草花粉变应原浸提物、其浸液及其制备方法
CN113679833A (zh) * 2020-05-19 2021-11-23 中国医学科学院北京协和医院 一种大籽蒿花粉致敏的动物模型的构建方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
EP0689601B1 (en) 1993-02-22 2006-10-04 The Rockefeller University Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
CZ20031653A3 (en) 2000-11-16 2004-03-17 Alk-Abelló A/S Mutant allergens
DK1499349T3 (da) 2001-03-02 2010-04-06 Univ Rockefeller Rekombinante hybrid-allergenkonstrukter med reduceret allergenitet, der bibeholder det naterulige allergens immunogenitet
CA2621067C (en) 2005-09-15 2014-04-29 Alk-Abello A/S A method for quantification of allergens
EP1897538A1 (en) 2006-08-23 2008-03-12 Stallergenes Sa Formulations for antigen-specific tolerance induction
US20080213252A1 (en) * 2007-01-03 2008-09-04 Ethan Lerner Methods of treating itch
EP2258391A1 (en) 2009-06-05 2010-12-08 Stallergenes S.A. Reduction of in vitro genotoxicity of pollen extracts by removal of flavonoids

Also Published As

Publication number Publication date
EP2692732A1 (en) 2014-02-05
EA029703B1 (ru) 2018-05-31
CN104981480A (zh) 2015-10-14
WO2014020179A1 (en) 2014-02-06
EP2880049A1 (en) 2015-06-10
EA201590303A1 (ru) 2015-07-30
US20150210742A1 (en) 2015-07-30
CA2881039A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
ZA201705114B (en) Cysteine protease
ZA201705113B (en) Cysteine protease
WO2013123432A3 (en) Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
PH12015501983A1 (en) Peptides and compositions for treatment of joint damage
WO2014124334A3 (en) Transthyretin antibodies and uses thereof
NZ737843A (en) Tau-binding antibodies
EA201691470A1 (ru) Белки, связывающие калликреин плазмы, и их применение для лечения наследственного ангионевротического отека
WO2017015622A3 (en) Gdf11 binding proteins and uses thereof
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
MX354481B (es) Anticuerpos dkk1 y métodos de uso.
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
MX2012001346A (es) Polipeptidos del factor ix modificados y usos de los mismos.
MX2017015817A (es) Anticuerpos de union a tau.
CR20160132A (es) Composiciones y método para tratar condiciones asociadas con el complemento
EA201390583A1 (ru) Композиции для улучшения состояния волос и соответствующие способы
EA029703B9 (ru) Новый аллерген из пыльцы амброзии и его применение
IN2014CN04071A (ru)
EP3511422A3 (en) Methods and compositions for diagnosing, prognosing, and treating endometriosis
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
WO2015031778A3 (en) Compositions and methods for the treatment or prevention of tuberculosis
EA201290792A1 (ru) Пептиды для вакцины против аллергии на березу
MX2011008179A (es) Peptidos para vacuna.
IN2015DN02501A (ru)
GB201118201D0 (en) Novel peptides

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU